It shows an affinity for the molecular targets important for the treatment of schizophrenia, in particular D2, 5-HT1A, and 5-HT2A receptors (Figure 1), and also reduces amphetamine-induced hyperactivity in mice, an experimental model predictive of antipsychotic activity in vivo. The gene discussed is HTR1A; the disease is schizophrenia.